...
首页> 外文期刊>American Journal of Epidemiology >Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking.
【24h】

Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking.

机译:高度神经胶质瘤与神经胶质瘤的关联具有等位基因以及过敏和吸烟史。

获取原文
获取原文并翻译 | 示例

摘要

Glioma risk has consistently been inversely associated with allergy history but not with smoking history despite putative biologic plausibility. Data from 855 high-grade glioma cases and 1,160 controls from 4 geographic regions of the United States during 1997-2008 were analyzed for interactions between allergy and smoking histories and inherited variants in 5 established glioma risk regions: 5p15.3 (TERT), 8q24.21 (CCDC26/MLZE), 9p21.3 (CDKN2B), 11q23.3 (PHLDB1/DDX6), and 20q13.3 (RTEL1). The inverse relation between allergy and glioma was stronger among those who did not (odds ratio(allergy-glioma) = 0.40, 95% confidence interval: 0.28, 0.58) versus those who did (odds ratio(allergy-glioma) = 0.76, 95% confidence interval: 0.59, 0.97; P(interaction) = 0.02) carry the 9p21.3 risk allele. However, the inverse association with allergy was stronger among those who carried (odds ratio(allergy-glioma) = 0.44, 95% confidence interval: 0.29, 0.68) versus those who did not carry (odds ratio(allergy-glioma) = 0.68, 95% confidence interval: 0.54, 0.86) the 20q13.3 glioma risk allele, but this interaction was not statistically significant (P = 0.14). No relation was observed between glioma risk and smoking (odds ratio = 0.92, 95% confidence interval: 0.77, 1.10; P = 0.37), and there were no interactions for glioma risk of smoking history with any of the risk alleles. The authors' observations are consistent with a recent report that the inherited glioma risk variants in chromosome regions 9p21.3 and 20q13.3 may modify the inverse association of allergy and glioma.
机译:胶质瘤的风险一直与变态反应史呈负相关,但与吸烟史无关,尽管其具有合理的生物学可行性。分析了1997-2008年来自美国4个地理区域的855例高级别神经胶质瘤病例和1160名对照的数据,分析了5个已建立的神经胶质瘤风险区域的过敏与吸烟史以及遗传变异之间的相互作用:5p15.3(TERT),8q24 .21(CCDC26 / MLZE),9p21.3(CDKN2B),11q23.3(PHLDB1 / DDX6)和20q13.3(RTEL1)。那些没有的人(几率(过敏-神经胶质瘤)= 0.40,95%置信区间:0.28,0.58)比那些没有的人(几率(过敏-神经胶质瘤)= 0.76,95)更强置信区间百分比:0.59,0.97; P(相互作用)= 0.02)携带9p21.3风险等位基因。但是,携带者(几率(过敏-神经胶质瘤)= 0.44,95%置信区间:0.29,0.68)与未携带者相比(几率/过敏-神经胶质瘤= 0.68, 95%置信区间:0.54、0.86)20q13.3胶质瘤风险等位基因,但这种相互作用在统计学上不显着(P = 0.14)。胶质瘤风险与吸烟之间没有关系(比值= 0.92,95%置信区间:0.77,1.10; P = 0.37),并且胶质瘤吸烟史与任何风险等位基因均无相互作用。作者的观察结果与最近的报道一致,即9p21.3和20q13.3染色体区域中遗传的神经胶质瘤风险变异可能会改变过敏与神经胶质瘤的逆相关性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号